Article

Starting Your Sterile Injectables Program Off On The Right Foot

By Jennifer Quint and Daniel Lenz, Pfizer CentreOne

iStock-1219894397-lab-cleanroom-computer-team

The successful sterile fill and finish of injectable drugs requires the highest levels of operational and quality excellence. Many variables must be considered and few cGMP manufacturing environments are as tightly controlled.  

Due to growing demand, the pharmaceutical industry’s need for sterile injectable (e.g., aseptic and terminal sterilization fill/finish) capacity will likely grow, as will the role of contract development and manufacturing organizations (CDMOs) in delivering such capacity.1  

How can drug sponsors and developers leverage these increasingly strategic commercial fill/finish partnerships? Product development experts Jennifer Quint and Daniel Lenz at Pfizer CentreOne offer their tips on how drug sponsors and developers can put programs on a firmer footing. 

VIEW THE ARTICLE!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Biosimilar Development? Subscribe today.

Subscribe to Biosimilar Development X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Biosimilar Development